Register Now: Webinar on Immunotherapy for Brain Tumors
Published:
Join Us for a Webinar on Immunotherapy for Brain Tumors
Immunotherapy – particularly the use of checkpoint inhibitors – has been a revolution in cancer care. However, not all cancers respond to checkpoint inhibitors, and the response rates are only 20-30%. Given the negative results in studies to treat one of the most deadly brain tumors, glioblastomas (GBM), using checkpoint inhibitors, novel immunotherapy strategies are needed.
Current approaches have employed the concept of multimodal strategies with immunotherapy. The central concept is to cause focal disruption to “kindle” a systemic immune response. For brain tumors, modalities such as focused ultrasound, stereotactic radiosurgery, neoadjuvant surgery, and laser ablation are being combined with immunotherapy strategies in hopes of generating an antitumor immune response.
Please register to join us at 1:00 PM Eastern on Monday, February 24, when Michael Lim, MD, will discuss the mechanisms of “kindling” and review the state of multimodal immunotherapy in GBM.
Michael Lim, MD Johns Hopkins University School of Medicine
WEBINAR Immunotherapy for Brain Tumors
Monday, February 24, 2020 1:00 PM Eastern US
About the Speaker
Dr. Michael Lim is a Professor of Neurosurgery, Oncology, Otolaryngology, and Radiation Oncology at the Johns Hopkins University School of Medicine.
He is also the Director of the Brain Tumor Immunotherapy Program at Johns Hopkins. His primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors, and their findings are directed towards translation to novel therapies against brain tumors.
In addition to running a laboratory, Dr. Lim also directs the immunotherapy clinical trials program at Johns Hopkins. He currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory.
Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors, and skull base tumors. He has extensive experience in new and innovative neurosurgical techniques including image guided surgery, microsurgery, minimally invasive procedures, and endoscopic surgery.
He obtained his MD from the Johns Hopkins University School of Medicine and completed his residency in Neurosurgery at Stanford University Hospital.
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
By using FUSF’s AI agent, you acknowledge and agree that your use is governed by FUSF’s Terms of Use Agreement. If you do not agree to be bound by the Terms of Use Agreement, you may not access or use FUSF’s AI agent.
